RT Journal Article
SR Electronic
A1 Misra-Press, Anita
T1 LUX-Lung 5
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 8
SP 13
OP 14
DO 10.1177/1559897715588299
UL http://mdc.sagepub.com/content/15/8/13.abstract
AB LUX-Lung 5 is the first prospective randomized, phase 3 trial to demonstrate superior progression-free survival by continuing afatinib plus paclitaxel as fourth-line treatment vs single-agent chemotherapy in patients with non–small cell lung cancer who had disease progression on chemotherapy with the combination of erlotinib plus gefitinib and with afatinib monotherapy with a manageable safety profile.